Tenaya director granted 120,000 stock options

Tenaya Therapeutics, Inc. director Catherine Stehman-Breen received a grant of stock options covering 120,000 shares of common stock.

Rhea-AI Filing Summary

Tenaya Therapeutics, Inc. director Catherine Stehman-Breen received a grant of stock options covering 120,000 shares of common stock. These options have an exercise price of $0.7989 per share and were granted as compensation, not through an open-market purchase.

The option grant was made under the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan and will vest in full on May 28, 2027, or earlier on the day immediately before the next annual meeting of stockholders after the grant date, if that comes first, provided she continues as a service provider. The options expire on May 27, 2036, and following this grant she holds 120,000 options of this award.

Insider Trade Summary

Grant/Award: 120,000 shares

Grant/Award 1 txn

Insider Stehman-Breen Catherine

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	120,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to buy) — 120,000 contracts (Direct)

Footnotes (1)

1. F1. Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

Key Figures

Option grant size: 120,000 options Exercise price: $0.7989 per share Underlying shares: 120,000 shares +3 more

6 metrics

Option grant size 120,000 options Stock Option (Right to buy) granted to director

Exercise price $0.7989 per share Conversion or exercise price of option grant

Underlying shares 120,000 shares Common Stock underlying the options

Post-transaction holdings (this award) 120,000 options Total options following transaction for this grant

Vesting date May 28, 2027 Full vesting date or earlier before next annual meeting

Expiration date May 27, 2036 Option term end date

Key Terms

Stock Option (Right to buy), exercise price, Equity Incentive Plan, vesting, +1 more

5 terms

Stock Option (Right to buy) financial

"security_title: "Stock Option (Right to buy)""

exercise price financial

"conversion_or_exercise_price: "0.7989""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Equity Incentive Plan financial

"Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vesting financial

"Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-05-27T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Catherine Stehman-Breen acquire in this Tenaya Therapeutics (TNYA) Form 4?

Catherine Stehman-Breen received a grant of stock options for 120,000 shares of Tenaya Therapeutics common stock. The options were awarded as compensation, not bought in the market, and give her the right to purchase shares at a fixed exercise price.

What is the exercise price of the stock options granted to the Tenaya Therapeutics (TNYA) director?

The stock options have an exercise price of $0.7989 per share. This means Stehman-Breen can purchase Tenaya Therapeutics common stock at $0.7989 per share once the options vest and before they expire, subject to the plan’s terms and her continued service.

When do Catherine Stehman-Breen’s Tenaya Therapeutics (TNYA) options vest and expire?

The options will vest in full on May 28, 2027, or earlier on the day immediately before the next annual meeting of stockholders after the grant date. They have an expiration date of May 27, 2036, defining the period during which they can be exercised.

How many Tenaya Therapeutics (TNYA) options does Catherine Stehman-Breen hold after this Form 4 transaction?

Following the reported grant, Stehman-Breen holds 120,000 stock options from this award. These options relate to 120,000 shares of Tenaya Therapeutics common stock and are subject to the vesting schedule and other conditions outlined in the company’s 2021 Equity Incentive Plan.

Is the Tenaya Therapeutics (TNYA) Form 4 transaction an open-market buy or a compensation grant?

The Form 4 shows a compensation-related grant, not an open-market purchase. The transaction is coded as an award of stock options under the Amended and Restated 2021 Equity Incentive Plan, with no cash purchase of shares reported in the transaction details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 07:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stehman-Breen Catherine

(Last) (First) (Middle)

C/O TENAYA THERAPEUTICS, INC.

171 OYSTER POINT BLVD., 5TH FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$0.7989	05/28/2026		A		120,000		05/28/2027(1)	05/27/2036	Common Stock	120,000	$0	120,000	D

Explanation of Responses:

1. Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

	/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)